Key facts
- This page summarizes Catherine Grassman's Form 4 filing for HESKA CORP.
- 11 reported transactions and 8 derivative rows are listed below.
- Accepted by SEC: 14 Jun 2023, 18:27.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Award
Disposed to Issuer
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Award
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Additional SEC filing notes
Section 16 status
Catherine Grassman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Footnote F1
Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 31, 2023, by and among the Issuer, Antech Diagnostics, Inc., a California corporation ("Acquiror"), Helsinki Merger Sub LLC, a Delaware limited liability company and a wholly-owned subsidiary of Acquiror, and, solely for purposes of Section 9.15 of the Merger Agreement, Mars, Incorporated, a Delaware corporation, these shares of performance-based restricted stock of the Issuer were fully accelerated assuming maximum level of performance immediately prior to the effectiveness of the merger.
Footnote F2
Pursuant to the Merger Agreement, these performance-based restricted stock units were fully accelerated assuming target level of performance immediately prior to the effectiveness of the merger.
Footnote F3
Disposed of pursuant to the Merger Agreement in exchange for cash consideration of $120.00 per share of common stock of the Issuer (the "Merger Consideration") on the effective date of the merger.
Footnote F4
Stock options of the Issuer became vested and exercisable upon achieving performance vesting conditions on February 28, 2022.
Footnote F5
Pursuant to the Merger Agreement, these stock options of the Issuer were fully accelerated assuming maximum level of performance immediately prior to the effectiveness of the merger.
Footnote F6
Stock options of the Issuer were canceled in the merger in exchange for an amount in cash equal to the difference, if any, between the Merger Consideration and the exercise price of such stock options.
Footnote F7
These stock options of the Issuer vested in two equal installments on December 31, 2021 and on December 31, 2022.
Footnote F8
These stock options of the Issuer vested as to two-thirds on June 1, 2020 and one-third on March 7, 2021.
Footnote F9
These stock options of the Issuer vested in three approximately equal annual installments beginning on March 7, 2019 and ending on March 7, 2021.